Inhibition of Hepatitis B Virus Production in Vitro by Proteasome Inhibitor MG132.

Yi Wang,Xiao-Liang Li,Yong-Sheng Yu,Zheng-Hao Tang,Guo-Qing Zang
DOI: https://doi.org/10.5754/hge11250
2013-01-01
Abstract:Background/Aims: To investigate the suppressive effects of proteasome inhibitor MG132 on hepatitis B virus production. Methodology: HepG2 2.2.15 hepatoblastoma cells, which constitutively produce HBV particles, were used in the present study. MTT assay was used to evaluate the cytotoxicity of MG132. A Proteasome-Glo chymotrypsin-like cell-based assay was used to access the proteasome activity. Quantitative PCR were performed to analyze HBV-DNA. Secreted HBV antigens in the culture medium were measured by ELISA. Western blot and immunofluorescent staining of HBV antigen were also performed. Results: After 6 days of MG132 treatment, proteasome activity was greatly decreased to 64.3 +/- 7.8% and 36.4 +/- 7.7% of untreated cells by 0.1 mu M and 0.3 mu M of MG132, respectively. The levels of HBsAg and HBeAg, and the copy number of extracellular HBV-DNA, were decreased to nearly half of the control group by 0.1 mu M MG132. The HBV replicative intermediates were also suppressed by MG132. Western blot and immunofluorescent staining clearly showed the lower levels of the expression of HBV proteins induced by MG132. Conclusions: MG132 could effectively inhibit the HBV replication in vitro. Ubiquitin-proteasome pathway plays an important role in HBV life cycle and could be a promising therapeutic target for anti-HBV drugs.
What problem does this paper attempt to address?